Dacarbazine, fluorouracil, and leucovorin in patients with advanced neuroendocrine tumors: A phase II trial

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 21, Issue 3, 1998, Pages 237-240

  Ollivier, Stéphane ^a   Fonck, M ^a   Becouarn Y ^a   Brunet, R ^a  

^a INSTITUT BERGONIÉ   (France)

Author keywords

Carcinoid; Chemotherapy; Dacarbazine; Fluorouracil; Leucovorin; Neuroendrocrine tumors

Indexed keywords

DACARBAZINE; FLUOROURACIL; FOLINIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CARCINOID; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; FEMALE; HUMAN; INSULINOMA; INTRAVENOUS DRUG ADMINISTRATION; LEUKOPENIA; MALE; MUCOSA INFLAMMATION; NEUROENDOCRINE TUMOR; PARAGANGLIOMA; PHASE 2 CLINICAL TRIAL; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOID TUMOR; DACARBAZINE; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; LEUKOPENIA; MALE; MIDDLE AGED; NAUSEA; NEOPLASMS, UNKNOWN PRIMARY; NEUROENDOCRINE TUMORS; SURVIVAL RATE;

EID: 0031865261     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-199806000-00005     Document Type: Article

References (16)

1. Pearse AGE. The cytochemistry and ultrastructure of polypeptide hormone-producing cells of the APUD series and the embryologic, physiologic and pathologic implications of the concept. J Histochem Cytochem 1969;17:303-13.
2. Heitz PU. Neuroendocrine markers in pathology. Acta Histochem 1990;38:35-43.
3. Wilander E, Grimelius L. Identification, characterization and classification of endocrine tumors. Zentralbl Pathol 1993;139: 95-100.
4. Frame J, Kelsen D, Kemeny N, et al. A phase II trial of streptozotocin and adriamycin in advanced APUD tumors. Am J Clin Oncol 1988;11:490-5.
5. Kessinger A, Foley JF, Lemon HM. Therapy of malignant APUD cell tumors. Effectiveness of DTIC. Cancer 1983;51: 790-4.
6. Moertel LG, Kvols LK, O'Connell MJ, et al. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991;68:227-32.
7. Rougier P, Oliveira J, Ducreux M, et al. Metastatic carcinoid and islet cell tumors of the pancreas: a phase II trial of the efficacy of combination chemotherapy with 5-fluorouraciI, doxorubicin and cisplatin. Eur J Cancer 1991;27:1380-2.
8. Bukowski RM, Johnson KG, Peterson RF, et al. A phase II trial of combination chemotherapy in patients with metastatic carcinoid tumors. A Southwest Oncology Group Study. Cancer 1987;60:2891-5.
9. Bukowski RM, Tangen LM, Peterson RF, et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group Study. Cancer 1994;73:1505-8.
10. Engstrom PF, Lavin PT, Moertel LG, et al. Streptozotocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 1984;2:1255-9.
11. Moertel LG, Lefkopoulo M, Lipsitz S, et al. Streptozotocin-doxorubicin, streptozotocin-fluorouracil or chlorozotocin in the treatment of advanced islet cell carcinoma. N Engl J Med 1992; 326:519-23.
12. Moertel LG, Johnson M, Mc Kusick MA, et al. The management of patients with advanced carcinoid tumors and islet cell carcinoma. Ann Intern Med 1994;120:302-9.
13. Moertel LG. An odyssey in the land of small tumors. J Clin Oncol 1987;5:1503-22.
14. Oberg K, Norheim I, Alm G. Treatment of malignant carcinoid tumors: a randomized controlled study of streptozotocin plus 5-FU and human leukocyte interferon. Eur J Cancer Clin Oncol 1989;10:1475-9.
15. Zilembo N, Buzzoni R, Bajetta E, et al. Salvage treatment after interferon alpha-2a in advanced neuroendocrine tumors. Acta Oncol 1993;32:245-50.
16. Garrow GC, Greco FA, Hainsworth JD. Poorly differentiated neuroendocrine carcinoma of unknown primary tumor site. Semin Oncol 1993;20:287-91.